Literature DB >> 16822093

Relapse prevention and recovery in the treatment of schizophrenia.

Nina R Schooler1.   

Abstract

Nonadherence to medication is a predictor of relapse in patients diagnosed with schizophrenia, and preventing relapse is crucial to achieving the goal of recovery. Long-term treatment with antipsychotics can be effective, although long-term patient response to medication may be difficult to predict from trials that measure response, remission, and relapse rates because they are often too short. Longer trials are needed to fully understand the implications of adherence and symptom remission in patient outcome. Recovery, however, is contingent on the stabilization of the symptoms of schizophrenia and the acquisition of the skills necessary to function in society. Psychosocial interventions, such as family psychoeducation, social skills training, and cognitive-behavioral therapy, used in conjunction with pharmacotherapy are effective in helping to prevent symptom relapse and promote functional recovery in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822093

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Perspectives on schizophrenia over the lifespan: a qualitative study.

Authors:  Sally Shepherd; Colin A Depp; Gloria Harris; Maureen Halpain; Lawrence A Palinkas; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2010-07-05       Impact factor: 9.306

2.  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Authors:  Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

3.  Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia.

Authors:  Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

Review 4.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

5.  Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.

Authors:  Rosaria Di Lorenzo; Michela Cameli; Marisa Bolondi; Giulia Landi; Valentina Moretti; Chiara Piemonte; Gabriella Pollutri
Journal:  Psychopharmacol Bull       Date:  2016-03-01

6.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

7.  Development of a recovery manual for suicidal patients with schizophrenia: consumer feedback.

Authors:  J Kasckow; C Appelt; G L Haas; S Huegel; L Fox; J Gurklis; S Zickmund; D Daley
Journal:  Community Ment Health J       Date:  2011-12-21

Review 8.  Managing suicide risk in patients with schizophrenia.

Authors:  John Kasckow; Kandi Felmet; Sidney Zisook
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

9.  Hospitalization and Some Sociodemographic Characteristics of Patients Registered with a Community Mental Health Center.

Authors:  Etem Erdal Erşan
Journal:  Community Ment Health J       Date:  2019-11-16

10.  Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Authors:  Peter F Buckley; Nina R Schooler; Donald C Goff; John Hsiao; Alexander Kopelowicz; John Lauriello; Theo Manschreck; Alan J Mendelowitz; Del D Miller; Joanne B Severe; Daniel R Wilson; Donna Ames; Juan Bustillo; Jim Mintz; John M Kane
Journal:  Schizophr Bull       Date:  2014-05-27       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.